Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $34.42.
SNDX has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Scotiabank lowered shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and dropped their target price for the company from $36.00 to $23.00 in a research report on Wednesday, January 31st. HC Wainwright reiterated a “buy” rating and set a $41.00 target price on shares of Syndax Pharmaceuticals in a research report on Wednesday, March 27th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research report on Friday, January 19th.
View Our Latest Stock Analysis on SNDX
Institutional Investors Weigh In On Syndax Pharmaceuticals
Syndax Pharmaceuticals Trading Down 0.9 %
Shares of NASDAQ:SNDX opened at $20.79 on Monday. The company has a 50 day moving average of $22.74 and a 200 day moving average of $19.49. The stock has a market cap of $1.77 billion, a P/E ratio of -7.02 and a beta of 1.03. Syndax Pharmaceuticals has a 12 month low of $11.22 and a 12 month high of $25.34.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same quarter in the prior year, the firm earned ($0.62) EPS. On average, equities analysts forecast that Syndax Pharmaceuticals will post -3.7 earnings per share for the current fiscal year.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Featured Stories
- Five stocks we like better than Syndax Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 5 discounted opportunities for dividend growth investors
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.